Cell Viability Assays Market Analysis

  • Report ID: 4785
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Cell Viability Assays Market Segmentation:

Application Segment Analysis

The stem cell research is anticipated to account for 52% share of the global cell viability assays market during the forecast period. The growth of this category can be attributed to increasing investments in stem cell research, and the Novo Nordisk Foundation's investment is expected to reach as high as USD 340 million over 10 years for the construction of a global Stem Cell Research Facility by 2022. The growth segment is also projected to benefit from an increase in the incidence of cardiovascular disease. The problems with the blood vessels cause cardiac disease most of the time. Stem cells that appear and function as normal blood vessels are used for the production of new blood vessels. In view of their ability to repair or regenerate various human tissues, stem cells from the bank can be used as a tool for people who are affected by conditions like vascular and cardiac disease.

Product Segment Analysis

Cell viability assays market from the consumables segment is expected to hold the largest share by the end of 2035. In view of the application of consumables for diagnostics, stem cell research, and pharmaceutical and biopharmaceutical research in particular, this segment is expected to experience significant growth with approximately 55 % market share over the forecast period. A large selection of nontoxic, ready-to-use, and highly immediate results reagents for cell viability assays is also available from a number of market participants.

Our in-depth analysis of the global market includes the following segments:

          Product

  • Consumables
  • Instrument  

          Application

  • Drug Discovery & Development
  • Stem Cell Research

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of cell viability assays is estimated at USD 2.9 billion.

The global cell viability assays market size was more than USD 2.68 billion in 2025 and is anticipated to grow at a CAGR of over 9.2%, reaching USD 6.46 billion revenue by 2035.

North America cell viability assays market is predicted to capture 38% share by 2035, driven by demand for cell-based therapies and R&D expansion.

Key players in the market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company (BD), PerkinElmer Inc., Promega Corporation, Biotium, Inc., Creative Bioarray, Abcam Plc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos